Korro Bio is a biotechnology company specializing in gene therapy whose RNA editing approach leverages already natural occurring processes.

Register for Details

For more details on financing and valuation of private companies similar to Korro Bio before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Korro Bio

To invest in Korro Bio pre-IPO

Can you invest in Korro Bio pre-IPO?

You may invest in Korro Bio as it is a public company listed on the NASDAQ with ticker KRRO. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Korro Bio before it goes public?

You can no longer sell shares of Korro Bio on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Korro Bio shares?

Forge can no longer determine the value of Korro Bio shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Korro Bio a publicly traded company?

Korro Bio became a public company following its SPAC on 11/06/2023 and is now traded on the NASDAQ under the ticker KRRO.

To learn more about Korro Bio potential IPO

Will Korro Bio go IPO?

Korro Bio became a public company following its SPAC on 11/06/2023 and is now traded on the NASDAQ under the ticker KRRO.

What is Korro Bio’s IPO price?

The IPO price of Korro Bio is not currently available.

When was Korro Bio founded?

Korro Bio was founded in 2018.

What is Korro Bio funding to date?

Korro Bio has raised $593.6MM to date.

Who are Korro Bio’s major investors?

Surveyor Capital
Invus
Sixty Degree Capital
Nea
Alexandria Venture Investments
Undisclosed Investors
Cormorant Asset Management
Fidelity
Verition Fund Management
Qiming Venture Partners
Point72
Wu Capital
Mp Healthcare Venture Management
Atlas Venture
Eventide Asset Management
Monashee Investment Management

Korro Bio Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
01/05/2022 Series B-1 $45.13MM $xx.xx $29.04B Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Eventide Asset Management, Fidelity, Invus, Monashee Investment Management, Mp Healthcare Venture Management, Nea, Point72, Qiming Venture Partners, Sixty Degree Capital, Surveyor Capital, Verition Fund Management, Wu Capital
Price per Share
$xx.xx
Shares Outstanding
17,289,273
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Eventide Asset Management, Fidelity, Invus, Monashee Investment Management, Mp Healthcare Venture Management, Nea, Point72, Qiming Venture Partners, Sixty Degree Capital, Surveyor Capital, Verition Fund Management, Wu Capital
01/05/2022 Series B-2 $45.12MM $xx.xx $29.04B Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Eventide Asset Management, Fidelity, Invus, Monashee Investment Management, Mp Healthcare Venture Management, Nea, Point72, Qiming Venture Partners, Sixty Degree Capital, Surveyor Capital, Verition Fund Management, Wu Capital
Price per Share
$xx.xx
Shares Outstanding
16,232,013
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Eventide Asset Management, Fidelity, Invus, Monashee Investment Management, Mp Healthcare Venture Management, Nea, Point72, Qiming Venture Partners, Sixty Degree Capital, Surveyor Capital, Verition Fund Management, Wu Capital
09/10/2020 Series A $91.5MM $xx.xx $17.48B Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Mp Healthcare Venture Management, Nea, Qiming Venture Partners, Surveyor Capital, Wu Capital
Price per Share
$xx.xx
Shares Outstanding
40,848,220
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, Mp Healthcare Venture Management, Nea, Qiming Venture Partners, Surveyor Capital, Wu Capital
12/31/2019 Series Seed 3 $10.12MM $xx.xx $2.99B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
7,780,769
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
05/24/2019 Series Seed 1 $4MM $xx.xx $1.2B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
05/24/2019 Series Seed 2 $2MM $xx.xx $1.2B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.